Novo Nordisk A/S

“Novo Nordisk operates one of the highest-quality pharmaceutical franchises globally — 65-75% ROIC, 45% operating margins, near-pristine balance sheet, and a decade-long reinvestment runway into a structurally underpenetrated GLP-1 market. The stock has de-rated ~46% from peak on legitimate competitive concerns (Lilly share gains, IRA pricing, pipeline disappointment) but the current 12-13x forward earnings multiple prices in near-zero long-term growth for a business with 60%+ ROE — an outcome far more pessimistic than the evidence supports. Competitive erosion is real but not existential; the risks are manageable and already embedded in the price. Base-case 10-year return is 2–2.5x with meaningful optionality if next-gen obesity pipeline succeeds.”